C 6872
Alternative Names: C-6872Latest Information Update: 18 Feb 2008
At a glance
- Originator Merck & Co
 - Class Cardiovascular therapies
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Atherosclerosis
 
Most Recent Events
- 01 Nov 2005 Phase-I clinical trials in Atherosclerosis in USA (unspecified route)